Investors & Media

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA

– BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential for extended dosing intervals – Biogen paid Ionis a $60 million one-time upfront payment CAMBRIDGE, Mass. and CARLSBAD, Calif. , Jan. 4, 2022 /PRNewswire/ —  Biogen Inc.

Read more
You are now leaving to visit